roche the swiss drug company which is one of the largest and fastestgrowing in the industry yesterday extended its involvement in genetic engineering by signing a deal to promote a new cystic fibrosis drug dnase made by genentech of the us writes daniel green dnase should be approved by 1994 sales could be as high as dollars 250m a year and roche will develop and promote the drug in europe the deal is the latest in a series following roches acquisition two years ago of a 60 per cent stake in genentech for dollars 21bn genentech was one of the pioneers in genetic engineering last year roche paid dollars 300m for a genetic engineering production process called pcr developed by cetus a us drug company